Literature DB >> 11804278

Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide.

C Mawrin1, V Aumann, E Kirches, R Schneider-Stock, C Scherlach, S Vogel, U Mittler, K Dietzmann, G Krause, S Weis.   

Abstract

Gliomatosis cerebri (GC) is a rare tumor of the central nervous system (CNS) characterized by widespread diffuse infiltration of the brain and spinal cord by neoplastic glial cells. We report the case of a 17-year-old boy with a bioptically diagnosed fibrillary astrocytoma. The administration of thalidomide, which was suggested to be beneficial in the treatment of human cancers, had no substantial clinical effect on our patient. Autopsy studies revealed a diffuse infiltration of the frontal and temporal lobes of the right hemisphere, brainstem, and the leptomeninges covering the whole spinal cord by an astrocytic tumor, which showed features both of low-grade astrocytoma and glioblastoma multiforme. No mutations in the p53 and PTEN tumor suppressor genes were found; immunoreactivities for p53, PTEN, and EGFR could not be detected.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11804278     DOI: 10.1023/a:1012982303419

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis.

Authors:  M F McCarty
Journal:  Med Hypotheses       Date:  1997-08       Impact factor: 1.538

2.  Clonal analysis of gliomas.

Authors:  M M Kattar; W J Kupsky; R K Shimoyama; T D Vo; M W Olson; G R Bargar; F H Sarkar
Journal:  Hum Pathol       Date:  1997-10       Impact factor: 3.466

3.  Radiologic-pathologic correlation. Gliomatosis cerebri.

Authors:  G J Felsberg; S A Silver; M T Brown; R D Tien
Journal:  AJNR Am J Neuroradiol       Date:  1994-10       Impact factor: 3.825

4.  Epidermal growth factor receptor expression and growth fraction in human tumours of the nervous system.

Authors:  G Reifenberger; R Prior; M Deckert; W Wechsler
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

Review 5.  A serial CT scan and MRI verification of diffuse cerebrospinal gliomatosis: a case report with stereotactic diagnosis and radiological confirmation.

Authors:  C Onal; C Bayindir; R Siraneci; N Izgi; I Yalçin; Z Altinel; O Barlas
Journal:  Pediatr Neurosurg       Date:  1996-08       Impact factor: 1.162

6.  Gliomatosis cerebri, report of a clinically diagnosed and histologically confirmed case.

Authors:  D Troost; H Kuiper; J Valk; P Fleury
Journal:  Clin Neurol Neurosurg       Date:  1987       Impact factor: 1.876

7.  p53 and PTEN gene mutations in gemistocytic astrocytomas.

Authors:  K Watanabe; A Peraud; C Gratas; S Wakai; P Kleihues; H Ohgaki
Journal:  Acta Neuropathol       Date:  1998-06       Impact factor: 17.088

8.  Primary central nervous system lymphoma presenting as diffuse cerebral infiltration.

Authors:  T Furusawa; K Okamoto; J Ito; N Kojima; K Oyanagi; S Tokiguchi; K Sakai
Journal:  Radiat Med       Date:  1998 Mar-Apr

9.  Gliomatosis cerebri: clinical features, treatment, and prognosis.

Authors:  D G Kim; H J Yang; I A Park; J G Chi; H W Jung; D H Han; K S Choi; B K Cho
Journal:  Acta Neurochir (Wien)       Date:  1998       Impact factor: 2.216

10.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Authors:  E P Sampaio; E N Sarno; R Galilly; Z A Cohn; G Kaplan
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more
  6 in total

1.  Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study.

Authors:  K Ina Ly; Derek H Oakley; Alexander B Pine; Matthew P Frosch; Sy Han Chiou; Rebecca A Betensky; Stuart R Pomerantz; Fred H Hochberg; Tracy T Batchelor; Daniel P Cahill; Jorg Dietrich
Journal:  Oncologist       Date:  2018-08-10

2.  Alterations of cell cycle regulators in gliomatosis cerebri.

Authors:  Christian Mawrin; Elmar Kirches; Regine Schneider-Stock; Carsten Boltze; Christian K Vorwerk; Andreas von Mawrin; Elmar Kirches; Regine Schneider-Stock; Carsten Boltze; Christian K Vorwerk; Andreas von Mawrin; Elmar Kirches; Regine Schneider-Stock; Carsten Boltze; Christian K Vorwerk; Andreas von Mawrin; Elmar Kirches; Regine Schneider-Stock; Carsten Boltze; Christian K Vorwerk; Andreas von Deimling; Gisela Stoltenburg-Didinge; Antje Bornemann; Bernd Romeike; Bernd Sellhaus; Knut Dietzmann
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

Review 3.  Gliomatosis cerebri in young patients' report of three cases and review of the literature.

Authors:  Alessandro Landi; Manolo Piccirilli; Cristina Mancarella; Felice Giangaspero; Maurizio Salvati
Journal:  Childs Nerv Syst       Date:  2010-04-08       Impact factor: 1.475

4.  Evaluation of molecular genetic alterations associated with tumor progression in a case of gliomatosis cerebri.

Authors:  Stefan Braeuninger; Regine Schneider-Stock; Elmar Kirches; James M Powers; David N Korones; Christian Mawrin
Journal:  J Neurooncol       Date:  2006-09-06       Impact factor: 4.130

5.  Mitochondrial DNA as a clonal tumor cell marker: gliomatosis cerebri.

Authors:  E Kirches; C Mawrin; R Schneider-Stock; G Krause; C Scherlach; K Dietzmann
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

6.  Assessment of tumor cell invasion factors in gliomatosis cerebri.

Authors:  Christian Mawrin; Thomas Schneider; Raimund Firsching; Falk R Wiedemann; Knut Dietzmann; Antje Bornemann; Bernd F M Romeike; Bernd Sellhaus; Andreas von Deimling
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.